Summit chief buys 30,000 shares

30th Jul 2014 16:48

AIM-listed drug developer Summit, which develops therapies for Duchenne Muscular Dystrophy and C. difficile infection, on Wednesday said its chief executive Glyn Edwards had acquired 30,000 shares. The 104.5p-a-share deal cost Edwards £31,350 and took his stake in the group to 233,333 shares. The news helped to lift the stock 2.42% to 106p.Top Director BuysEnergy XXI (Bermuda) (DI) (EXXI) Director name: Mr John Daniel Schiller JrAmount purchased: 18,007 @ $21.24 Value: $382,469Intelligent Energy Holdings (IEH) Director name: Dr. Henri WinandAmount purchased: 37,472 @ 232.17p Value: £86,999Summit Corporation (SUMM) Director name: Mr Glyn EdwardsAmount purchased: 30,000 @ 104.50p Value: £31,350Top Director SellsQinetiQ Group (QQ.) Director name: Mr Leo QuinnAmount sold: 309,102 @ 208.00p Value: £642,932QinetiQ Group (QQ.) Director name: Mr David MellorsAmount sold: 154,551 @ 208.00p Value: £321,466Marks & Spencer Group (MKS) Director name: Mr John Dixon Amount sold: 46,242 @ 438.50p Value: £202,771Marks & Spencer Group (MKS) Director name: Mr John Dixon Amount sold: 28,925 @ 438.50p Value: £126,836Spectris (SXS) Director name: Mr Clive WatsonAmount sold: 1,941 @ 1,915.50p Value: £37,180NR